Promotions & Moves

AGC Biologics Makes Executive Changes

Mark Womack to succeed Robert Broeze, as chief business officer

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AGC Biologics has made a change in executive leadership, appointed by their board of directors. Robert Broeze will retire on March 5, 2019 after a career spanning over 35 years in the biopharmaceutical industry. Mark Womack, previously the senior vice president of integration management and business excellence for AGC Biologics, will succeed Bob as the chief business officer, effective immediately.   Bob joined CMC Biologics (now AGC Biologics) in 2015 as senior vice president of global busine...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters